Reach your audience. Get results.
Rely on the experience, guidance, and superior media targeting of Business Wire for your global press release distribution.
Public RelationsMaximize the reach of your news with our press release distribution services and partnerships. Investor RelationsReach and engage investors, shareholders, analysts, and media with our complete suite of IR services and tools. Distribution & AnalyticsTarget your news, reach your audiences, and understand the impact of your press releases with our analytics reports. |
Latest News
Today is June 02, 2024.
All times in Eastern Daylight Time.
-
ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated ComputingSECAUCUS, N.J.--(BUSINESS WIRE)--ZT Systems, a leading provider of accelerated computing solutions for artificial intelligence (AI) and cloud, today announced its ACX200 platform featuring the NVID... more »
-
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for EnterprisesPALO ALTO, Calif.--(BUSINESS WIRE)--Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises. more »
-
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AIRIYADH, Saudi Arabia--(BUSINESS WIRE)--Denodo Opens ME regional head office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI more »
-
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placeboWILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful imp... more »
-
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerFOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 s... more »
-
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 s... more »
-
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine TherapyTOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU Demonstrated a Median PFS of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow mBC Following One or More Lines of Endocrine Therapy more »
-
Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients On Treatment and Those Searching for and Participating in Clinical Trials in the United States and EuropeCHICAGO--(BUSINESS WIRE)--ASCO Annual Meeting – Massive Bio, a renowned leader in AI-driven oncology solutions and Mika Health, the premier oncology digital therapeutic platform, today announced a ... more »
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapyWILMINGTON, Del.--(BUSINESS WIRE)--Detailed positive results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significan... more »
-
Accutar Biotechnology在2024年ASCO年會上公布了在ER陽性/HER2陰性乳癌病患中展開AC699單一療法第一期試驗的資料紐澤西州克蘭伯里--(BUSINESS WIRE)--(美國商業資訊)-- Accutar Biotechnology, Inc.是一家專注於人工智慧(AI)支援的藥物研發的生物科技公司。該公司今天公布了其正在進行的在雌激素受體(ER)陽性/人表皮生長因數受體2 (HER2)陰性局部晚期或轉移性乳癌病患中展開AC699單一療法第一期試驗的資料。相關資料將於2024年6月1日在伊利諾州芝加哥舉... more »
-
June Joy at Juicy Stakes CasinoST JOHN’S, Antigua--(BUSINESS WIRE)--You know the drill. New month, same old Juicy Stakes Casino – bringing you a scorching set of specials with summer now firmly in sight. To mark the start of a v... more »
-
Bihar collabora con Bidgely per ridurre i furti di energia e le perdite di ricavi tramite l'analisi dei dati alimentata dall'IALOS ALTOS, Calif. e BANGALORE, India--(BUSINESS WIRE)--La società di partecipazione elettrica dello Stato del Bihar (BSPHCL) ha adottato l'intelligenza artificiale (IA) di Bidgely Energy Theft Solu... more »
-
Accutar Biotechnology、ASCO 2024にてER +/ HER2-乳がん患者におけるAC699単剤療法の第1相試験データを発表クランベリー、ニュージャージー州--(BUSINESS WIRE)--(ビジネスワイヤ) -- 人工知能(AI)対応創薬に焦点を当てたバイオテクノロジー企業のAccutar Biotechnology, Inc.は、ER陽性/HER2陰性の局所進行性または転移性乳がん患者を対象とした、現行のAC699単剤療法第1相試験データを発表しました。同データは、6月1日にイリノイ州シカゴで開催の米国臨... more »
-
Accutar Biotechnology在2024年ASCO年会上公布了在ER+/HER2-乳腺癌患者中开展AC699单一疗法一期试验的数据新泽西州克兰伯里--(BUSINESS WIRE)--(美国商业资讯)-- Accutar Biotechnology, Inc.是一家专注于人工智能支持的药物研发的生物科技公司,今天公布了该公司正在进行的在雌激素受体(ER)阳性/人表皮生长因子受体2阴性(HER2-)局部晚期或转移性乳腺癌患者中开展AC699单一疗法一期试验的数据。相关数据将于2024年6月1日在伊利诺伊州芝加哥举行的美国... more »
-
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven ... more »